Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP7214 in mild symptomatic COVID-19
NCT05007236Phase 2Completed
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RP7214 in coronavirus disease 2019 (COVID-19), sponsored by Rhizen Pharmaceuticals AG. Started Sep 2021; status: completed.
02
Drugs
RP7214
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05007236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007236.